Clinical Trials

Date: 2018-01-04

Type of information: Initiation of development program



Company: Adocia (France)

Product: BioChaperone® teduglutide

Action mechanism:

  • peptide. Teduglutide is a novel, recombinant analogue of human glucagon-like peptide 2 (GLP-2), a naturally occurring protein involved in the rehabilitation of the intestinal lining. It has been developed to reduce dependence on parenteral nutrition (PN) in adult patients with short bowel syndrome (SBS).
  • Adocia’s proprietary BioChaperone technology is designed to deliver meaningful enhancement of single agents and enable the combination of multiple therapeutic proteins into a ready-to-use formulation.

Disease: short bowel syndrome

Therapeutic area: Rare diseases - Gastrointestinal diseases


Trial details:

Latest news:

  • • On January 4, 2018, Adocia announced an update of its corporate strategy. The company is expanding application of its proprietary BioChaperone® technology beyond diabetes. Adocia is now applying this technology to BioChaperone® teduglutide for the treatment of short bowel syndrome The first project to be announced as part of this expanded strategy is BioChaperone® Teduglutide. Teduglutide (Gattex®) is approved for the management of short bowel syndrome as a once-daily injectable. It is currently marketed as a lyophilizate in a kit, requiring multiple reconstitution stages prior to each daily injection. By solubilizing and stabilizing teduglutide in an aqueous formulation, BioChaperone technology may deliver significant improvement to the daily life of people living with short bowel syndrome. The program is now in preclinical testing. Other pipeline candidates are currently under evaluation.

Is general: Yes